Bio-Techne Corporation's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026A larger company is purchasing Bio-Techne; shareholders will receive $73 cash per share if approved.
Companies publicly announced their merger plan so investors and the public know about the major transaction.
Investors review quarterly earnings reports to understand if the company is making or losing money.
Strong earnings reports help investors decide if the company is healthy; dividends return profit to shareholders.
Leadership changes affect company direction; new executives bring different experience and strategy.
Quarterly reports show whether a company is growing, shrinking, or staying the same.
Regular quarterly updates and dividends show the company is performing well and sharing profits.
Stocky reads Bio-Techne Corporation's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Bio-Techne Corporation's most recent tracked filing was a 8-K on 26 Jun 2026: Merck KGaA agrees to buy Bio-Techne for $73 per share.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.